{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T17:08:27Z","timestamp":1779296907975,"version":"3.51.4"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82503187"],"award-info":[{"award-number":["82503187"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82403417"],"award-info":[{"award-number":["82403417"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018537","name":"National Science and Technology Major Project","doi-asserted-by":"publisher","award":["2024ZD0525806"],"award-info":[{"award-number":["2024ZD0525806"]}],"id":[{"id":"10.13039\/501100018537","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ejca.2026.116743","type":"journal-article","created":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T17:03:41Z","timestamp":1776013421000},"page":"116743","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["An open-label, two-cohort, phase 1a\/b study of weekly irinotecan hydrochloride liposome injection combined with vincristine and temozolomide (NALIRI-VT) in patients with advanced Ewing sarcoma"],"prefix":"10.1016","volume":"240","author":[{"given":"Yuwei","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiyang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7584-6006","authenticated-orcid":false,"given":"Changjiang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weikang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fangzhou","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tingting","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4772-6592","authenticated-orcid":false,"given":"Lu","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9097-3249","authenticated-orcid":false,"given":"Xiaodong","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2026.116743_bib1","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28355","article-title":"Ewing sarcoma","volume":"68","author":"Eaton","year":"2021","journal-title":"Pedia Blood Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2026.116743_bib2","doi-asserted-by":"crossref","first-page":"348","DOI":"10.3892\/ol.2016.4575","article-title":"Management of recurrent or refractory ewing sarcoma: a systematic review of phase ii clinical trials in the last 15 years","volume":"18","author":"Xu","year":"2019","journal-title":"Oncol Lett"},{"issue":"5","key":"10.1016\/j.ejca.2026.116743_bib3","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/BF00686188","article-title":"Efficacy of topoisomerase i inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors","volume":"36","author":"Houghton","year":"1995","journal-title":"Cancer Chemother Pharm"},{"issue":"6","key":"10.1016\/j.ejca.2026.116743_bib4","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1158\/1078-0432.CCR-22-3546","article-title":"Longer versus shorter schedules of vincristine, irinotecan, and temozolomide (vit) for relapsed or refractory ewing sarcoma: a randomized controlled phase 2 trial","volume":"29","author":"Xu","year":"2023","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"19","key":"10.1016\/j.ejca.2026.116743_bib5","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1200\/JCO.23.02110","article-title":"Resilient part 2: a randomized, open-label phase iii study of liposomal irinotecan versus topotecan in adults with relapsed small cell lung cancer","volume":"42","author":"Spigel","year":"2024","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116743_bib6","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejca.2018.12.007","article-title":"Napoli-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: final overall survival analysis and characteristics of long-term survivors","volume":"108","author":"Wang-Gillam","year":"2019","journal-title":"Eur J Cancer (Oxf Engl 1990)"},{"issue":"11","key":"10.1016\/j.ejca.2026.116743_bib7","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1002\/ijc.34531","article-title":"China special issue on gastrointestinal tumors-cetuximab retreatment plus camrelizumab and liposomal irinotecan in patients with ras wild-type metastatic colorectal cancer: cohort b of the phase ii crack study","volume":"153","author":"Quan","year":"2023","journal-title":"Int J Cancer"},{"issue":"11 Pt 2","key":"10.1016\/j.ejca.2026.116743_bib8","doi-asserted-by":"crossref","first-page":"237S","DOI":"10.1093\/ajh\/2.11.237S","article-title":"Antihypertensive action of beta-adrenoceptor blocking drugs. The role of intrarenal mechanisms","volume":"2","author":"Struyker-Boudier","year":"1989","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.ejca.2026.116743_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2024.124273","article-title":"Quantitative determination of liposomal irinotecan and sn-38 concentrations in plasma samples from children with solid tumors: use of a cryoprotectant solution to enhance liposome stability","volume":"1245","author":"Nair","year":"2024","journal-title":"J Chromatogr B Anal Technol Biomed Life Sci"},{"issue":"7","key":"10.1016\/j.ejca.2026.116743_bib10","doi-asserted-by":"crossref","first-page":"e1256","DOI":"10.1002\/onco.13726","article-title":"Anlotinib, vincristine, and irinotecan for advanced ewing sarcoma after failure of standard multimodal therapy: a two-cohort, phase ib\/ii trial","volume":"26","author":"Xu","year":"2021","journal-title":"Oncologist"},{"issue":"7","key":"10.1016\/j.ejca.2026.116743_bib11","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1111\/cas.15377","article-title":"Liposomal irinotecan (onivyde): exemplifying the benefits of nanotherapeutic drugs","volume":"113","author":"Milano","year":"2022","journal-title":"Cancer Sci"},{"issue":"10018","key":"10.1016\/j.ejca.2026.116743_bib12","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0140-6736(15)00986-1","article-title":"Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (napoli-1): a global, randomised, open-label, phase 3 trial","volume":"387","author":"Wang-Gillam","year":"2016","journal-title":"Lancet (Lond Engl)"},{"issue":"1","key":"10.1016\/j.ejca.2026.116743_bib13","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.50756","article-title":"Nalirifox, folfirinox, and gemcitabine with nab-paclitaxel as first-line chemotherapy for metastatic pancreatic cancer: a systematic review and meta-analysis","volume":"7","author":"Nichetti","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.ejca.2026.116743_bib14","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/s41392-024-01948-4","article-title":"Irinotecan hydrochloride liposome hr070803 in combination with 5-fluorouracil and leucovorin in locally advanced or metastatic pancreatic ductal adenocarcinoma following prior gemcitabine-based therapy (pan-heroic-1): a phase 3 trial","volume":"9","author":"Cui","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"19","key":"10.1016\/j.ejca.2026.116743_bib15","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1200\/JCO.23.02110","article-title":"Resilient part 2: a randomized, open-label phase iii study of liposomal irinotecan versus topotecan in adults with relapsed small cell lung cancer","volume":"42","author":"Spigel","year":"2024","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2026.116743_bib16","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1002\/cam4.635","article-title":"Pepcol: a gercor randomized phase ii study of nanoliposomal irinotecan pep02 (mm-398) or irinotecan with leucovorin\/5-fluorouracil as second-line therapy in metastatic colorectal cancer","volume":"5","author":"Chibaudel","year":"2016","journal-title":"Cancer Med"},{"issue":"19","key":"10.1016\/j.ejca.2026.116743_bib17","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1200\/JCO.23.02110","article-title":"Resilient part 2: a randomized, open-label phase iii study of liposomal irinotecan versus topotecan in adults with relapsed small cell lung cancer","volume":"42","author":"Spigel","year":"2024","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2026.116743_bib18","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1111\/cas.15377","article-title":"Liposomal irinotecan (onivyde): exemplifying the benefits of nanotherapeutic drugs","volume":"113","author":"Milano","year":"2022","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ejca.2026.116743_bib19","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ejca.2020.06.014","article-title":"A phase i trial of talazoparib and irinotecan with and without temozolomide in children and young adults with recurrent or refractory solid malignancies","volume":"137","author":"Federico","year":"2020","journal-title":"Eur J Cancer (Oxf Engl 1990)"},{"key":"10.1016\/j.ejca.2026.116743_bib20","series-title":"Onitt: a phase i study of nanoliposomal irinotecan with talazoparib or temozolomide in children and young adults with recurrent or refractory solid tumors","author":"Federico","year":"2025"},{"issue":"1","key":"10.1016\/j.ejca.2026.116743_bib21","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.30005","article-title":"Irinotecan dose schedule for the treatment of ewing sarcoma","volume":"70","author":"Slotkin","year":"2023","journal-title":"Pedia Blood Cancer"},{"issue":"9","key":"10.1016\/j.ejca.2026.116743_bib22","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/pbc.24547","article-title":"Pilot study of vincristine, oral irinotecan, and temozolomide (voit regimen) combined with bevacizumab in pediatric patients with recurrent solid tumors or brain tumors","volume":"60","author":"Wagner","year":"2013","journal-title":"Pedia Blood Cancer"},{"issue":"6","key":"10.1016\/j.ejca.2026.116743_bib23","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1002\/pbc.22206","article-title":"Irinotecan and temozolomide for ewing sarcoma: the memorial sloan-kettering experience","volume":"53","author":"Casey","year":"2009","journal-title":"Pedia Blood Cancer"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926005241?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926005241?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T16:23:18Z","timestamp":1779294198000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926005241"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":23,"alternative-id":["S0959804926005241"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116743","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An open-label, two-cohort, phase 1a\/b study of weekly irinotecan hydrochloride liposome injection combined with vincristine and temozolomide (NALIRI-VT) in patients with advanced Ewing sarcoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116743","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"116743"}}